A Phase 1/2A Prospective, Dose-Escalation, Open-Label Study of the Safety, Feasibility, and Initial Efficacy of Subcutaneous Plasminogen (Human) 10 for the Treatment of Diabetic Foot Ulcer
Phase of Trial: Phase II
Latest Information Update: 25 Apr 2019
Price : $35 *
At a glance
- Drugs Plasminogen (Primary)
- Indications Diabetic foot ulcer
- Focus Adverse reactions
- Sponsors ProMetic Biosciences
- 25 Apr 2019 Status changed from recruiting to completed.
- 04 Mar 2018 Status changed from not yet recruiting to recruiting.
- 01 Nov 2017 New trial record